MDGL Quote, Financials, Valuation and Earnings

Amgen, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 33.55%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Amgen, Inc.'s return on equity of 95.55%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $563.80, signalling downside risk potential of -2.78%. On the other hand Amgen, Inc. has an analysts' consensus of $324.25 which suggests that it could fall by -6.13%. Given that Amgen, Inc. has more downside risk than Madrigal Pharmaceuticals, Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Amgen, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.76% to investors and pays a quarterly dividend of $2.38 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amgen, Inc.'s PE ratio is 26.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.36x versus 5.21x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 10.24%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $563.80, signalling downside risk potential of -2.78%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.90 which suggests that it could grow by 62.58%. Given that Amicus Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Amicus Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.36x versus 5.00x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -259.95%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Insmed, Inc.'s return on equity of -193.23%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $563.80, signalling downside risk potential of -2.78%. On the other hand Insmed, Inc. has an analysts' consensus of $220.41 which suggests that it could grow by 6.59%. Given that Insmed, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Insmed, Inc. quarterly revenues of $142.3M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is higher than Insmed, Inc.'s net income of -$370M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.36x versus 88.00x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of -39.75% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 81.15%. Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56% beat Krystal Biotech, Inc.'s return on equity of 19.91%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $563.80, signalling downside risk potential of -2.78%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $217.70 which suggests that it could grow by 2.55%. Given that Krystal Biotech, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Krystal Biotech, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -1.034, which suggesting that the stock is 203.399% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.528%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $287.3M, which are larger than Krystal Biotech, Inc. quarterly revenues of $97.8M. Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M is lower than Krystal Biotech, Inc.'s net income of $79.4M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Krystal Biotech, Inc.'s PE ratio is 32.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 17.36x versus 17.39x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.